Positive Study Ongoing Study Data from AMG 510 in Patients with Previous Treated KRAS G12C-Mutated Solid Tumors

Amgen (AMGN) announced new data from its ongoing Phase I clinical trial evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. AMG 510 is a first-in-class investigational oral therapy designed to selectively and irreversibly target the...

Erasmus MC-Sophia Children’s Hospital Study Falls Short in Using Everolimus to Treat Autism & Intellectual Disability Symptoms

Erasmus MC-Sophia Children’s Hospital, Rotterdam led a clinical trial that unfortunately fell short in their hopes that a drug used for tumors and epilepsy in people with tuberous sclerosis complex, failed to boost the patients’ intelligence or ease autism traits....

Pin It on Pinterest